Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2401-2404

  Freese, Andrew ^a   During, Matthew J ^b,c   Davidson, Beverly L ^d   Gennarelli, Thomas A ^e   Kaplitt, Michael G ^f   Flamm, Eugene S ^a   Snyder, Peter J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF IOWA   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; TETRAHYDROBIOPTERIN; TYROSINE; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CASE REPORT; DOPAMINE METABOLISM; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA;

ADENOMA; ADENOVIRIDAE; ADULT; DOPAMINE; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LEVODOPA; MALE; PITUITARY GLAND, ANTERIOR; PITUITARY NEOPLASMS; PROLACTIN; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

ADENOVIRIDAE;

EID: 0029993148     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.6.2401     Document Type: Article

References (12)

1. Bression D. 1980 Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. J Clin Endocrinol Metab. 51: 1037-1044.
2. Vance ML, Evans WS, Thorner M.O. 1984 Bromocriptine. Ann Int Med. 100, 78-91.
3. Tindall GT, Kovacs K, Horvath E, Thorner MO. 1982 Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab. 55: 1178-1183.
4. Bassetti M, Spada A, Pezzo G, Giannatasio G. 1984 Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab. 58: 268-273.
5. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endo Rev 13: 220-240.
6. Thorner MO, Martin WH, Rogol AD, et al. 1980 Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab. 51: 438-445.
7. Molitch ME, Elton RL, Blackwell RE, et al. 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 60: 698-705.
8. Molitch ME, Prolactinoma, in Melmed S. The Pituitary. Blackwell Science, Cambridge, p465, 1995.
9. Snyder PJ, Bashey HM, Phillips JL, Gennarelli TA. 1985 Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture. J Clin Endocrinol Metab. 61: 1061-1065.
10. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. 1993 A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics 3: 219-223.
11. Kobayashi K, Kiuchi K, Ishii A, et al. 1988 Expresson of four types of human tyrosine hydroxylase in COS cells. FEBS Letters 238: 431-434.
12. Geller AI, During MJ, Oh YJ, Freese A, O'Malley K. 1995 An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-DOPA from cultured rat striatal cells. J Neurochem 64: 487-496.